The current stock price of HOTH is 1.1018 USD. In the past month the price decreased by -2.8%. In the past year, price decreased by -30.67%.
ChartMill assigns a fundamental rating of 2 / 10 to HOTH. HOTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months HOTH reported a non-GAAP Earnings per Share(EPS) of -1.06. The EPS increased by 20.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -131.58% | ||
| ROE | -147.77% | ||
| Debt/Equity | 0 |
7 analysts have analysed HOTH and the average price target is 4.59 USD. This implies a price increase of 316.59% is expected in the next year compared to the current price of 1.1018.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.38 | 984.90B | ||
| JNJ | JOHNSON & JOHNSON | 20.94 | 523.67B | ||
| MRK | MERCK & CO. INC. | 12.31 | 269.11B | ||
| PFE | PFIZER INC | 7.97 | 145.07B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.41B | ||
| ZTS | ZOETIS INC | 19.65 | 54.90B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.63 | 22.85B | ||
| VTRS | VIATRIS INC | 5.44 | 14.60B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.85 | 12.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.20B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.46B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.66B |
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
HOTH THERAPEUTICS INC
1177 Avenue Of The Americas, 5Th Floor Suite 5066
New York City NEW YORK 10020 US
CEO: Robb Knie
Employees: 2
Phone: 16467562997
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
The current stock price of HOTH is 1.1018 USD. The price increased by 5.94% in the last trading session.
HOTH does not pay a dividend.
HOTH has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
HOTH THERAPEUTICS INC (HOTH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.06).
HOTH THERAPEUTICS INC (HOTH) currently has 2 employees.